Novo Nordisk (NVO) closed at $50.96 in the latest trading session, marking a +2.6% move from the prior day. The stock's change was more than the S&P 500's daily gain of 0.21%. Elsewhere, the Dow gained 1.03%, while the tech-heavy Nasdaq lost 0.22%.

The stock of drugmaker has risen by 2.75% in the past month, leading the Medical sector's loss of 0.43% and the S&P 500's gain of 1.7%.

Market participants will be closely following the financial results of Novo Nordisk in its upcoming release. The company's upcoming EPS is projected at $0.82, signifying a 15.46% drop compared to the same quarter of the previous year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $11.27 billion, down 3.58% from the year-ago period.

For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $3.39 per share and a revenue of $44.61 billion, representing changes of -14.39% and -4.63%, respectively, from the prior year.

It's also important for investors to be aware of any recent modifications to analyst estimates for Novo Nordisk. These revisions help to show the ever-changing nature of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.

Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.

The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.96% lower. At present, Novo Nordisk boasts a Zacks Rank of #5 (Strong Sell).

In terms of valuation, Novo Nordisk is presently being traded at a Forward P/E ratio of 14.67. This valuation marks a discount compared to its industry average Forward P/E of 17.68.

Meanwhile, NVO's PEG ratio is currently 4.53. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Large Cap Pharmaceuticals industry had an average PEG ratio of 2.69 as trading concluded yesterday.

The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 231, putting it in the bottom 7% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.

Beyond Nvidia: AI's Second Wave Is Here

The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.

See Stocks Now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 

Novo Nordisk A/S (NVO): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research